Anixa Biosciences treats second patient in cohort 5 of Phase 1 ovarian cancer CAR-T trial
ANIX•Anixa Biosciences treated a second patient in cohort 5 of its Phase 1 FSHR-targeted CAR-T trial for recurrent ovarian cancer. The company reported no dose-limiting toxicities so far across cohorts and said multiple patients in the heavily pre-treated population have lived more than one year after treatment, including one beyond two years.
1. Trial enrollment update
Anixa said it treated a second patient in cohort 5 of its ongoing Phase 1 trial. Results have not been presented. The company reported no dose-limiting toxicities across cohorts so far, including in the first patient treated at the highest dose level.
2. Interim observations
Management said multiple patients in the heavily pre-treated population have lived more than one year after treatment, including one beyond two years.
